NALM-6
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The NALM-6 cell line originated from blood cultures collected from a 19-year-old male patient who had been diagnosed with non-T, non-B acute lymphoblastic leukemia (ALL) during a relapse. These cultures yielded 8 “leukemia” and 2 “normal-B” cell lines. Interestingly, at the time of culture, the leukemic blasts displayed a unique membrane phenotype, characterized by the presence of SmIg (lambda and mu chain immunoglobulins), Ia-like B cell associated antigen (Ia), and the common form of ALL specific antigen (cALL). This phenotype differed from the typical non-T, non-B ALL phenotype seen at the disease’s onset. Among the 8 established leukemia cell lines (designated as NALM 6-13), variations in membrane phenotype expression were evident, despite the shared cytogenetic markers (5q- and 12p+) and monoclonal SmIg (lambda, mu). These observations suggest the potential for limited intra-clonal differentiation within the leukemia clone.
Why choose NALM-6 from AcceGen?
The NALM-6 cell line from AcceGen is characterized by its high viability and exceptional quality, maintained through stringent quality control measures. These cells are consistently monitored for sterility, ensuring the absence of bacteria and fungi, and confirmed to be negative for mycoplasma using PCR-based assays. Furthermore, they have been rigorously tested and found to be free of human pathogens such as EBV, HBV, HCV, HHV-8, HIV-1, HIV-2, HTLV-1/2, MLV, and SMRV, guaranteeing their suitability for diverse research applications.
| Product Code | Nalm-6; NALM 6; Nalm 6; NALM6; Nalm6; NALM-6-M1 |
| Species | Human |
| Cat.No | ABC-TC252S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
NALM-6 cell line finds valuable applications in the study of human acute lymphoblastic leukemia, providing essential insights into the disease and serving as a foundational tool for potential treatment strategies. Researchers use NALM-6 to explore various aspects of leukemia, including the detection and potential accumulation of oxidative clustered DNA lesions in leukemia cells when exposed to radiation doses akin to those employed in radiotherapy. These investigations not only deepen our understanding of leukemia but also contribute to the development of innovative therapeutic approaches for this challenging condition.
NALM-6 cell line were originally isolated from peripheral blood of a patient with acute lymphoblastic leukemia (ALL) in relapse.
The seeding density is 2 × 10^5 cells/mL, it is recommended to keep the cell concentration within the range of 1 × 10^5 to 1 × 10^6 cells/mL for optimal growth.
The utility of Nalm-6 cells extends to studying the efficacy of therapeutic targets and existing drug resistance mechanisms, provides a unique way for researching the genomic landscape of the disease, including genomic instability and DNA repair mechanisms. It can also be helpful for studying the complex nature of acute leukemia.
The doubling time of NALM-6 cell line is around 35 to 40 hours. It could be different due to the batches.
